je.st
news
KEYTRUDA (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
2015-10-09 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KEYTRUDA is Currently Approved in 39 Countries, including the United States and throughout the European Union KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a draft recommendation, in the form of a Final Appraisal Determination (FAD), recommending KEYTRUDA (pembrolizumab) as a first-line treatment option for adults with advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-236-1130orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: for
advanced
health
care
Category:Biotechnology and Pharmaceuticals